Accessibility setting


Select language

Skip to secondary menu

Skip to content

Jehovah’s Witnesses


Cost-Effectiveness of Blood Transfusion Alternatives

Hematology (Oncology)

Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece.

Nikolaidi E, Hatzikou M, Geitona M.

Source‎: Cost Eff Resour Alloc 2013;11(1):16.

Indexed‎: PubMed 23870502

DOI‎: 10.1186/1478-7547-11-16

The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA).

Reitan JF, Kudrik FJ, Fox K, van Breda A, Shreay S, Corey-Lisle PK.

Source‎: J Med Econ 2013;16(5):633-8.

Indexed‎: PubMed 23425291

DOI‎: 10.3111/13696998.2013.778269

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe.

Deger M, Eisterer W, Kutikova L, Salek S.

Source‎: Support Care Cancer 2013;21(2):485-93.

Indexed‎: PubMed 22825456

DOI‎: 10.1007/s00520-012-1538-0

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients.

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Source‎: Cancer 2013;119(1):107-14.

Indexed‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation.

Lightdale JR, Randolph AG, Tran CM, Jiang H, Colon A, Houlahan K, Billet A, Sloan S, Lehmann LE.

Source‎: Biol Blood Marrow Transplant 2012;18(5):813-7.

Indexed‎: PubMed 22080050

DOI‎: 10.1016/j.bbmt.2011.10.043

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Source‎: Support Care Cancer 2012;20(1):159-65.

Indexed‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom.

Guest JF, Watson HG, Limaye S.

Source‎: Clin Ther 2010;32(14):2478-93.

Indexed‎: PubMed 21353116

DOI‎: 10.1016/j.clinthera.2011.01.011

Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.

Stallworth JR, Jerrell JM, Tripathi A.

Source‎: Am J Hematol 2010;85(10):795-7.

Indexed‎: PubMed 20645429

DOI‎: 10.1002/ajh.21772

Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction.

Sarode R, Refaai MA, Matevosyan K, Burner JD, Hampton S, Rutherford C.

Source‎: Transfusion 2010;50(2):487-92.

Indexed‎: PubMed 19804569

DOI‎: 10.1111/j.1537-2995.2009.02413.x

The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.

Borg S, Glenngård AH, Osterborg A, Persson U.

Source‎: Acta Oncol 2008;47(6):1009-17.

Indexed‎: PubMed 18770060

DOI‎: 10.1080/02841860701744498

Should intravenous iron be the standard of care in oncology?

Auerbach M.

Source‎: J Clin Oncol 2008;26(10):1579-81.

Indexed‎: PubMed 18375888

DOI‎: 10.1200/JCO.2007.15.4609

Cost of outpatient blood transfusion in cancer patients.

Crémieux PY, Barrett B, Anderson K, Slavin MB.

Source‎: J Clin Oncol 2000;18(14):2755-61.

Indexed‎: PubMed 10894876

The medical section of is designed as an informational resource primarily for use by clinicians and other health-care professionals. It provides neither medical advice nor treatment recommendations and does not substitute for an appropriately qualified health-care provider. The clinical literature cited is not published by Jehovah’s Witnesses, but it outlines transfusion-alternative strategies that might be considered. It is the responsibility of each qualified health-care provider to maintain awareness of new information, discuss options for care, and assist patients in making choices in accord with their medical condition, wishes, values, and beliefs. Not all listed strategies are appropriate or acceptable to all patients.

Patients: Always seek the advice of your doctor or other qualified health-care provider regarding medical conditions or treatments. Check with a doctor if you suspect you are ill.

The use of this website is governed by its terms of use.